Trazodone, a phenylpiperazine?triazolopyridine antidepressant, was originally discovered and developed in Italy in the 1970s by Angelini research laboratories. Trazodone is used to treat depression and to treat the combination of symptoms of anxiety and depression. Like most antidepressants, trazodone has also been used in limited numbers of patients to treat panic disorder, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, enuresis (bed-wetting), eating disorders such as bulimia nervosa, cocaine dependency, and the depressive phase of bipolar (manic-depressive) disorder. It should be noted, however, that trazodone has not received official approval from the United States Food and Drug Administration (FDA) for these secondary uses. Scope of the Report: This report focuses on the Trazodone Hydrochloride (API) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Only few manufacturers can produce trazodone hydrochloride (API) in USA. Teva, the Israeli company, has a production base in the United States, dominates the market with the production market share of 92.98% in 2015 The price of trazodone hydrochloride (API) has a overall upward trend from 2011 to 2016, with a little decrease in 2012 and 2015. The average price of trazodone hydrochloride (API) is about 218 USD/Kg in 2015. The average product profit margin is about 55.82% in 2015, and it also experienced fluctuations in recent years. The worldwide market for Trazodone Hydrochloride (API) is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. Market Segment by Manufacturers, this report covers Teva Angelini Mylan Fermion The Piramal Group Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Type, covers Trazodone Hydrochloride (API) Others Market Segment by Applications, can be divided into Antidepression Anxiolytic Hypnotic Others There are 15 Chapters to deeply display the global Trazodone Hydrochloride (API) market. Chapter 1, to describe Trazodone Hydrochloride (API) Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of Trazodone Hydrochloride (API), with sales, revenue, and price of Trazodone Hydrochloride (API), in 2016 and 2017; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of Trazodone Hydrochloride (API), for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions; Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018; Chapter 12, Trazodone Hydrochloride (API) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023; Chapter 13, 14 and 15, to describe Trazodone Hydrochloride (API) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Table of Contents 1 Market Overview 1.1 Trazodone Hydrochloride (API) Introduction 1.2 Market Analysis by Type 1.2.1 Trazodone Hydrochloride (API) 1.2.2 Others 1.3 Market Analysis by Applications 1.3.1 Antidepression 1.3.2 Anxiolytic 1.3.3 Hypnotic 1.3.4 Others 1.4 Market Analysis by Regions 1.4.1 North America (
